Compass Pathways plc - ADR is a clinical-stage biotechnology company focused on mental health care. Compass Pathways develops COMP360, a proprietary synthetic psilocybin therapy being studied for treatment-resistant depression and other psychiatric conditions, including post-traumatic stress disorder and anorexia nervosa. The company’s work centers on evidence-based psychedelic medicine, combining drug development with psychotherapy-oriented treatment models. Based in London, Compass Pathways operates across the United Kingdom and the United States and serves as a specialist participant in the emerging mental health therapeutics market. Its current business is centered on advancing investigational treatments through clinical trials and preparing for broader medical use if approved.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$394M
▼ -85.6% YoY
Op. Margin
–
ROIC
-124.80%
▼ -69.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$161M
▼ -31.9% YoY
Op. Cash Flow (TTM)
-$161M
▼ -31.9% YoY
Net Debt
-$115M
Net Cash Position
Cash & Equiv.
$150M
Continue Research
Peers
Medical Care Facilities · Pick stocks to compare with CMPS
Held by ETFs
CMPS is in 13 US ETFs. The largest of them, with CMPS's weight in each:
iShares Biotechnology ETFIBB0.10%of the fund
ARK Genomic Revolution ETFARKG3.25%of the fund
- APActivePassive International Equity ETFAPIE0.02%of the fund
SPDR S&P International Small Cap ETFGWX0.13%of the fund
ProShares Ultra Nasdaq BiotechnologyBIB0.06%of the fund
Compass Pathways (CMPS) in three numbers
Questions about Compass Pathways
Is Compass Pathways a high-quality business?
Compass Pathways scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from company filings. Its best check is net debt at -$115M, and its weakest is return on capital at -124.8%. The Quality tab shows every check against its target.
Does Compass Pathways (CMPS) pay a dividend?
No. Compass Pathways (CMPS) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 4 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing CMPS
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.